Sanofi SA Company Profile (EPA:SAN)

About Sanofi SA (EPA:SAN)

Sanofi SA logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: EPA:SAN
  • CUSIP: N/A
  • Web: en.sanofi.com
Average Prices:
  • 50 Day Moving Avg: €25.48
  • 200 Day Moving Avg: €25.74
P/E:
  • Trailing P/E Ratio: 11.44
  • P/E Growth: 2.12
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: 14.63%
 

Frequently Asked Questions for Sanofi SA (EPA:SAN)

What is Sanofi SA's stock symbol?

Sanofi SA trades on the EPA under the ticker symbol "SAN."

Where is Sanofi SA's stock going? Where will Sanofi SA's stock price be in 2017?

16 analysts have issued 12-month price objectives for Sanofi SA's shares. Their predictions range from €75.00 to €100.00. On average, they anticipate Sanofi SA's stock price to reach €88.60 in the next twelve months. View Analyst Ratings for Sanofi SA.

Who are some of Sanofi SA's key competitors?

Who are Sanofi SA's key executives?

Sanofi SA's management team includes the folowing people:

  • Serge Weinberg, Independent Chairman of the Board
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee and the Senior Leadership Team
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel, Member of the Executive Committee and the Senior Leadership Team
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets, Member of the Executive Committee and the Senior Leadership Team
  • Peter Guenter, Executive Vice President and General Manager, Diabetes & Cardiovascular, Member of the Executive Committee and the Senior Leadership Team
  • Carsten Hellmann, Executive Vice President and General Manager of Merial, Member of the Executive Committee and the Senior Leadership Team
  • David Loew, Executive Vice President and General Manager of Sanofi Pasteur, Member of the Executive Committee and the Senior Leadership Team
  • David P. Meeker M.D., Executive Vice President and General Manager of Sanofi Genzyme, Member of the Executive Committee and the Senior Leadership Team
  • Roberto Pucci, Executive Vice President, Human Resources, Member of the Executive Committee and the Senior Leadership Team


MarketBeat Community Rating for Sanofi SA (EPA SAN)
Community Ranking:  2.3 out of 5 ( )
Outperform Votes:  322 (Vote Outperform)
Underperform Votes:  381 (Vote Underperform)
Total Votes:  703
MarketBeat's community ratings are surveys of what our community members think about Sanofi SA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sanofi SA (EPA:SAN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 9 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.19)
Consensus Price Target: €88.60

Analysts' Ratings History for Sanofi SA (EPA:SAN)
Show:
DateFirmActionRatingPrice TargetDetails
7/20/2017J P Morgan Chase & CoReiterated RatingNeutralView Rating Details
7/4/2017Credit Suisse GroupSet Price TargetBuy€95.00View Rating Details
6/16/2017Jefferies Group LLCSet Price TargetNeutral€90.00View Rating Details
6/6/2017Morgan StanleySet Price TargetBuy€91.00View Rating Details
5/24/2017Goldman Sachs Group, Inc. (The)Set Price TargetNeutral€82.00View Rating Details
5/20/2017Berenberg BankSet Price TargetNeutral€97.00View Rating Details
5/8/2017Barclays PLCSet Price TargetSell€75.00View Rating Details
5/2/2017Deutsche Bank AGSet Price TargetBuy€96.00View Rating Details
5/2/2017Sanford C. BernsteinSet Price TargetNeutral€91.00View Rating Details
4/28/2017S&P GlobalSet Price TargetNeutral€90.00View Rating Details
4/12/2017Kepler Capital MarketsSet Price TargetBuy€92.00View Rating Details
4/7/2017HSBC Holdings plcSet Price TargetSell€77.00View Rating Details
3/23/2017Societe GeneraleSet Price TargetBuy€100.00View Rating Details
1/6/2017Citigroup Inc.Reiterated RatingNeutralView Rating Details
12/6/2016S&P Global Inc.Set Price TargetNeutral€80.00View Rating Details
9/14/2016BNP ParibasSet Price TargetNeutral€78.00View Rating Details
6/30/2016Independent Research GmbHSet Price TargetNeutral€77.00View Rating Details
6/9/2016Baader BankSet Price TargetNeutral€78.00View Rating Details
2/9/2016S&P Equity ResearchSet Price TargetBuy€85.00View Rating Details
(Data available from 7/20/2015 forward)

Earnings

Earnings History for Sanofi SA (EPA:SAN)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Sanofi SA (EPA:SAN)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Sanofi SA (EPA:SAN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sanofi SA (EPA:SAN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Sanofi SA (EPA:SAN)
Latest Headlines for Sanofi SA (EPA:SAN)
Source:
DateHeadline
americanbankingnews.com logoSanofi SA (SAN) Rating Reiterated by J P Morgan Chase & Co
www.americanbankingnews.com - July 20 at 10:53 AM
bloomberg.com logoRoad to Brexit: The Heartlands Where a Good Deal Matters Most - Bloomberg
www.bloomberg.com - July 13 at 9:08 AM
finance.yahoo.com logoSanofi: Pre-quarterly Results Communication
finance.yahoo.com - July 13 at 9:08 AM
reuters.com logoSanofi lawsuit over Novo Nordisk diabetes drug marketing narrowed
www.reuters.com - July 12 at 7:42 AM
thestreet.com logoSanofi Steps Up M&A Activity With $650 Million Purchase of Protein Sciences - TheStreet.com
www.thestreet.com - July 12 at 7:42 AM
reuters.com logoSanofi lawsuit over Novo Nordisk diabetes drug marketing narrowed - Reuters
www.reuters.com - July 12 at 7:42 AM
prnewswire.com logoChronic Kidney Disease (CKD) Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast ... - PR Newswire (press release)
www.prnewswire.com - July 11 at 7:23 AM
marketwatch.com logoSanofi to buy vaccine maker Protein Sciences - MarketWatch
www.marketwatch.com - July 11 at 7:23 AM
finance.yahoo.com logoEuropean stocks stuck in tight ranges as traders wait for Yellen
finance.yahoo.com - July 11 at 7:23 AM
americanbankingnews.com logoSanofi SA (SAN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - July 10 at 11:14 AM
finance.yahoo.com logoAlnylam Pharmaceuticals, Inc. Stock Perked Up 14% in June -- Here's Why
finance.yahoo.com - July 7 at 9:42 AM
reuters.com logoPfizer receives token payment to exit Brazil venture, sources say ... - Reuters
www.reuters.com - July 6 at 8:46 AM
News IconPfizer receives token payment to exit Brazil venture, sources say - Business Insider
www.businessinsider.com - July 5 at 10:20 AM
americanbankingnews.com logoCredit Suisse Group Analysts Give Sanofi SA (SAN) a €95.00 Price Target
www.americanbankingnews.com - July 4 at 7:25 AM
bloomberg.com logoBuoyant Europe Stocks Turn Out to Be `Pain Trade' of First Half - Bloomberg
www.bloomberg.com - July 1 at 7:12 AM
nasdaq.com logoIMF Lowers US Growth Outlook: International ETFs to Buy - Nasdaq
www.nasdaq.com - June 29 at 6:43 AM
bloomberg.com logoDomino Effect: Nestle Sale of L'Oreal Could Trigger Sanofi Move - Bloomberg
www.bloomberg.com - June 27 at 8:02 AM
finance.yahoo.com logoSanofi Announces Licensing of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA) in the European Union
finance.yahoo.com - June 27 at 8:02 AM
finance.yahoo.com logoGood Companies From Warren Buffett's Portfolio
finance.yahoo.com - June 25 at 8:07 PM
nasdaq.com logoGood Companies From Warren Buffett's Portfolio - Nasdaq.com - Nasdaq
www.nasdaq.com - June 25 at 5:33 AM
americanbankingnews.com logoJ P Morgan Chase & Co Analysts Give Sanofi SA (SAN) a €95.00 Price Target
www.americanbankingnews.com - June 22 at 8:04 AM
americanbankingnews.com logoSanofi SA (SAN) Given a €90.00 Price Target by Jefferies Group LLC Analysts
www.americanbankingnews.com - June 17 at 11:08 AM
finance.yahoo.com logoSanofi chief says U.S. Supreme Court ruling on biologics has "immediate impact"
finance.yahoo.com - June 16 at 9:34 AM
finance.yahoo.com logoInformation concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
finance.yahoo.com - June 15 at 12:20 AM
finance.yahoo.com logoStart Your Morning With a Cup of Coffee and an Ounce of Dengue Prevention
finance.yahoo.com - June 15 at 12:20 AM
nasdaq.com logoETFs in Focus on Macron's Likely Parliamentary Election Win
www.nasdaq.com - June 13 at 7:44 PM
investorplace.com logo3 Large Cap Pharma Stocks to Buy Now (HLUYY, BAYRY, SNY) - Investorplace.com
investorplace.com - June 13 at 10:16 AM
americanbankingnews.com logoSanofi SA (SAN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - June 13 at 8:46 AM
finance.yahoo.com logoAre Sanofi, Gilead In A Bidding War Over This Small-Cap Biotech?
finance.yahoo.com - June 12 at 4:21 PM
finance.yahoo.com logoIs Regeneron, Sanofi's Eczema Drug Headed For Blockbuster Status?
finance.yahoo.com - June 12 at 4:21 PM
finance.yahoo.com logoNew Analysis Shows Sanofi's Soliqua® 100/33 Lowered HbA1c by More Than 2 Percent in Patients with Screening Levels Greater than 9 Percent
finance.yahoo.com - June 10 at 7:42 PM
finance.yahoo.com logoIn Senior Adults Treated with Basal Insulin, Switching to Sanofi's Toujeo® Halved Hypoglycemia Risk
finance.yahoo.com - June 10 at 7:42 PM
americanbankingnews.com logoSanofi SA (SAN) Given a €91.00 Price Target at Morgan Stanley
www.americanbankingnews.com - June 6 at 9:18 AM
finance.yahoo.com logoSanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - June 4 at 7:48 PM
finance.yahoo.com logoRegeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - June 4 at 7:48 PM
finance.yahoo.com logoPerformance of Sanofi’s Established Prescription Products in 1Q17
finance.yahoo.com - May 29 at 6:37 PM
finance.yahoo.com logoSanofi’s Generics and Consumer Healthcare Business in 1Q17
finance.yahoo.com - May 29 at 6:37 PM
americanbankingnews.com logoGoldman Sachs Group Inc Analysts Give Sanofi SA (SAN) a €82.00 Price Target
www.americanbankingnews.com - May 24 at 7:14 AM
News IconUPDATE 1-Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval
www.businessinsider.com - May 23 at 9:29 AM
reuters.com logoRegeneron, Sanofi rheumatoid arthritis drug wins US approval - Reuters
www.reuters.com - May 22 at 6:46 PM
americanbankingnews.com logoSanofi SA (SAN) PT Set at €92.00 by Jefferies Group LLC
www.americanbankingnews.com - May 21 at 4:20 PM
americanbankingnews.com logoSanofi SA (SAN) PT Set at €97.00 by Berenberg Bank
www.americanbankingnews.com - May 20 at 10:02 PM
americanbankingnews.com logoSanofi SA (SAN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 19 at 9:22 AM
seekingalpha.com logoRegeneron Will Still Be Heavily Reliant On Eylea Even If Sarilumab Becomes A Blockbuster
seekingalpha.com - May 16 at 7:34 PM
finance.yahoo.com logoInformation concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce...
finance.yahoo.com - May 16 at 7:33 PM
finance.yahoo.com logo[$$] Big pharma hopes rule change will ease China sales pain
finance.yahoo.com - May 16 at 7:33 PM
americanbankingnews.com logoSanofi SA (SAN) Given a €97.00 Price Target by Berenberg Bank Analysts
www.americanbankingnews.com - May 14 at 2:14 PM
americanbankingnews.com logoSanofi SA (SAN) Given a €92.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - May 12 at 9:53 AM
finance.yahoo.com logoAllegra® Allergy Gears Up for Bike to Work Day Across the U.S.
finance.yahoo.com - May 11 at 8:06 PM
finance.yahoo.com logoThere could a better way to protect against the flu, and it has implications for tackling HIV and the common cold
finance.yahoo.com - May 11 at 8:06 PM

Social

Social activity is not available for this stock.
This page was last updated on 7/20/2017 by MarketBeat.com Staff